Skip to content

Second India‑US Drug Policy Working Group Meeting Highlights Joint Strategy

By News Analysis India · · 1 min read

The Narcotics Control Bureau convened the second India‑US Drug Policy Executive Working Group in Delhi on 2‑3 November, bringing together policy makers and law‑enforcement officials from the two nations. Leading the Indian delegation was NCB’s Director‑General Anurag Garg, while the U.S. side was represented by Debbie Seguin, Acting Deputy Director of the Office of National Drug Control Policy, and Sara Carter, the agency’s director and chief drug czar.

During the session, officials detailed the India Vision Roadmap 2026‑2029, a strategy devised under the direction of Prime Minister Narendra Modi and Home Minister Amit Shah. The roadmap outlines a network‑centric investigative model, tighter control of drug precursors, financial tracking, preventive outreach and rehabilitation initiatives. Garg reiterated that India’s approach aims to dismantle the full drug‑trafficking ecosystem, addressing financiers, suppliers, facilitators and logistics networks.

Carter emphasized the importance of the bilateral executive working group in disrupting international drug‑smuggling chains and curbing the flow of synthetic drugs and precursor chemicals into worldwide markets. She referenced President Trump’s 2026 National Drug Control Strategy, which describes modern criminal networks as operating like sophisticated multinational logistics firms, demanding an equally sophisticated counter‑strategy.

Ambassador Sergio Gor added that the partnership is delivering concrete, on‑the‑ground results, including blocking illegal chemical supplies, safeguarding commercial supply routes and neutralising cartels that exploit these substances. The meeting also noted advances made since the first executive group session held in Washington in January 2026, including cooperation on Operations Medmax and Wipe and the endorsement of India’s voluntary precursor‑chemical code of conduct. Both parties committed to sustained institutional interaction, rapid intelligence exchange and coordinated enforcement actions to address new drug‑related threats.